跳至主要内容
临床试验/JPRN-UMIN000000767
JPRN-UMIN000000767
已完成
未知

Phase-I/IIa study of radiofrequency ablation combined with in situ application of immunoadjuvant, Cal-TUMP - R-Cal-TUMP

Kanazawa university0 个研究点目标入组 16 人2010年4月1日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Hepatocellular carcinoma
发起方
Kanazawa university
入组人数
16
状态
已完成
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2010年4月1日
结束日期
2011年3月1日
最后更新
2年前
研究类型
Interventional
性别
All

研究者

入排标准

入选标准

  • 未提供

排除标准

  • Exclusion criteria 1\) Past history of other caner except hepatocellular carcinoma in recent 5 year, or present affecting cancer 2\) Past history of autoimmune disease or present affecting autoimmune disease 3\) Infected HIV 4\) Technically difficult main tumor for radiofrequency ablation 5\) Difficult for this treatment because of hematological disease or bleeding tendency 6\) Uncontrolled diseases such as sever infectious disease, severe cardiac disease and psychological diseases 7\) (1\) Systemic administration of anti\-cancer drugs or steroid, (2\) Radiological or biological treatment which may affect to systemic condition, within 4 weeks before this treatment 8\) Pregnant or nursing woman or person who has the possibility of pregnancy and plan to pregnant 9\)Affecting tuberculosis, or more than 2 cm in diameter induration reaction positive after skin reaction test using immune adjuvant specially made in our hospital 10\) inadequate cases by principle doctor including uncertainty to adherent to treatment protocol

结局指标

主要结局

未指定

相似试验